What's Happening?
Johnson & Johnson has announced the launch of its VARIPULSE Pro platform in Europe, following CE Mark approval. This development marks a significant advancement in the company's pulsed field ablation (PFA) portfolio. The VARIPULSE Pro introduces a new
pulse sequence designed to improve procedural efficiency and safety. It features a lower temperature profile and an ablation process that is five times faster than its predecessor, while maintaining equivalent lesion quality. The platform integrates with the CARTO 3 System, utilizing advanced mapping capabilities for precise lesion delivery. Initial cases have been performed under the VARIPURE multicenter study, with the company committed to generating further evidence through ongoing clinical studies.
Why It's Important?
The launch of VARIPULSE Pro is significant as it represents a major step forward in the treatment of atrial fibrillation, a common cardiac arrhythmia affecting over 50 million people worldwide. By enhancing procedural efficiency and safety, Johnson & Johnson aims to improve patient outcomes and support healthcare professionals in delivering high-quality care. The integration of advanced mapping and navigation technologies positions the company as a leader in the field of cardiac ablation, addressing significant unmet needs in cardiovascular care. This innovation could potentially reduce procedure times and improve the precision of treatments, benefiting both patients and healthcare providers.
What's Next?
Johnson & Johnson plans to feature the VARIPULSE Pro platform at the European Heart Rhythm Association (EHRA) annual meeting, where it will conduct live case demonstrations and hands-on training sessions. The company will also present 12-month interim results from the ongoing VARIPURE study. While the VARIPULSE Pro is not yet approved in the United States, its success in Europe could pave the way for future regulatory approvals and market expansion. The company is expected to continue its focus on innovation and evidence generation to support the adoption of its PFA technologies globally.
